RWE in asthma – alk

RWE in asthma

Time to REACT in AIT

5 Key results
Results from REACT, the first major study within the REWEAL programme. It's time to REACT in AIT.
5 Key results

Potential new AIT benefits
Beyond relevant outcomes in allergic rhinitis (AR) and asthma, the REACT study also revealed potential new findings related to allergy immunotherapy (AIT), such as reduced risk of pneumonia and hospitalisations. Read more here.
Potential new benefits

Effectiveness of AIT in asthma
The REACT study demonstrated the long-term benefits of allergy immunotherapy (AIT) for patients with allergic rhinitis (AR) and pre-existing asthma, across several clinically relevant asthma outcomes. Read more here.
Effectiveness of AIT in asthma

The REACT study cohort
The REACT study included a total of 92,048 patients with allergic rhinitis (AR) with or without asthma. Half of the cohort was treated with allergy immunotherapy (AIT). Read more to learn about the characteristics of these real-life patients.
The REACT cohort